Phase 2 Start
IRD: Phase 2 Start: A Phase 1b/2a Open-Label, Dose-Exploration Study to Investigate the Safety and Tolerability of Subre
September 1, 2026 · leber. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- September 1, 2026
- Company
- Opus Genetics, Inc. (IRD)
- Drug
- leber
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 2 Start~month
Phase 2 Start: A Phase 1b/2a Open-Label, Dose-Exploration Study to Investigate the Safety and Tolerability of Subre
- Company
- Opus Genetics, Inc. (IRD)
- Drug
- leber
- Indication
- Leber Congenital Amaurosis; Leber Congenital Amaurosis (LCA)